Drug Trial Radar · NCT02566252
Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)
Last checked: Nov 19, 2026Latest source record: Aug 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jul 2015
Primary completion
Jan 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- Pulmotect, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- WCCT Global
- First posted
- Oct 2, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study evaluates the effect of pre-treatment with either cromolyn sodium or albuterol sulfate on the safety and tolerability or PUL-042 Inhalation Solution in healthy subjects.
Conditions
- Healthy
Interventions
PUL-042 Inhalation SolutionDrug
PUL-042
Cromolyn SodiumDrug
Pre-treatment
Albuterol sulfateDrug
Pre-treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent, treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0)Time frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
WCCT Global
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.